Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to characterize the safety and tolerability profile of TAK-137 when administered as a single dose of tablets at escalating dose levels in healthy participants.

Detailed Description
-----------------
The drug being tested in this study is called TAK-137. TAK-137 is being tested to find a safe and well-tolerated dose. This study looked at safety (lab results and side effects) and pharmacokinetic properties (drug absorption, distribution, metabolism, and excretion) in people who took TAK-137. This study was designed as a single ascending 6 Cohort dose study with planned doses of 2, 5, 15, 50, and 100 mg and Cohort 6 dose to be determined if the maximum tolerated dose (MTD) was not reached. Anticipated enrollment was 48. This study enrolled 47 participants and consisted of 6 Cohorts. Participants in Cohorts 1, 2, 3, 5 and 6 were randomized to receive a single dose of TAK-137 or placebo after a 10-hour fast. Participants in Cohort 4 were randomized to receive a single dose of TAK-137 or placebo under fasted conditions, followed by a single dose of TAK-137 or placebo under fed conditions 14 days later. Participants in cohort 4 will receive the same dose in both fasted and fed conditions. The starting dose was 2 mg followed by administrations of 5, 10, 0.5 and 20 mg. This single-center trial was conducted in the United States. For Cohorts 1, 2, 3, 5, and 6 the overall time to participate in this study was up to 42 days. Participants made 4 visits to the clinic including one 5-day period of confinement to the clinic, and were contacted by telephone 14 days after last dose of study drug for a follow-up assessment. For Cohort 4 the overall time to participate in this study was up to 56 days. Participants made 7 visits to the clinic including two 5-day periods of confinement to the clinic, and were contacted by telephone 14 days after last dose of study drug for a follow-up assessment.

Official Title
-----------------
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-137 in Healthy Subjects

Conditions
-----------------
Dose Finding Study

Intervention / Treatment
-----------------
* Drug: TAK-137
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is a healthy male or non-pregnant, non-lactating female adult who is 18 to 55 years of age inclusive at the time of informed consent and first study medication dose. Weighs at least 45 kg and has a body mass index (BMI) between 18 and 30.0 kg/m^2, inclusive at Screening. Is able to comply with the protocol and is willing to sign the informed consent prior to undergoing any study-related procedures. Exclusion Criteria: Has a known hypersensitivity to any component of the formulation of TAK-137. Has a medical condition such as mental retardation that can cause cognitive impairment. Has a risk of suicide according to the Investigator's clinical judgment (eg, per Columbia-Suicide Severity Rating Scale [C-SSRS] or has made a suicide attempt in the previous 6 months). Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the participant's medical history, physical examination, or safety laboratory tests (including safety electroencephalogram [EEG]) giving reasonable suspicion of a disease that would contraindicate taking TAK-137, or a similar drug in the same class, or that might interfere with the conduct of the study. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias. Has taken any excluded medication, supplements, or food products listed in the Excluded Medications and Dietary Products table.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1: TAK-137 2 mg<br>TAK-137 2 mg, tablets, orally, once on Day 1. | Drug: TAK-137<br>* TAK-137 tablets<br>|
| Experimental: Cohort 2: TAK-137 5 mg<br>TAK-137 5 mg, tablets, orally, once on Day 1. | Drug: TAK-137<br>* TAK-137 tablets<br>|
| Experimental: Cohort 3: TAK-137 10 mg<br>TAK-137 10 mg, tablets, orally, once on Day 1. | Drug: TAK-137<br>* TAK-137 tablets<br>|
| Experimental: Cohort 4: TAK-137 5 mg Food Effect<br>TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2. | Drug: TAK-137<br>* TAK-137 tablets<br>|
| Experimental: Cohort 5: TAK-137 0.5 mg<br>TAK-137 0.5 mg, tablets, orally, once on Day 1. | Drug: TAK-137<br>* TAK-137 tablets<br>|
| Experimental: Cohort 6: TAK-137 20 mg<br>TAK-137 20 mg, tablets, orally, once on Day 1. | Drug: TAK-137<br>* TAK-137 tablets<br>|
| Placebo Comparator: Cohorts 1-6: Placebo<br>TAK-137 placebo-matching tablets, orally, once on Day 1. | Drug: Placebo<br>* TAK-137 placebo-matching tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event | An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug. | Day 1 to 14 days after the last dose of study medication(Up to 30 days) | 
| Percentage of Participants With Abnormal Safety Laboratory Findings | The percentage of participants with any markedly abnormal standard safety laboratory values was collected throughout study. | Day 1 to 14 days after the last dose of study medication (Up to 30 Days) | 
| Percentage of Participants With Markedly Abnormal Vital Sign Measurements | The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study. | Day 1 to 14 days after the last dose of study medication | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax: Maximum Observed Plasma Concentration for TAK-137 | Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. | Day 1 | 
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-137 | Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax. | Day 1 | 
| AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-137 | (AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]). | Day 1 | 
| AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-137 | AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity. | Day 1 | 
| Terminal Elimination Half-life (T1/2) for TAK-137_101 | Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma. | Day 1 | 
| Apparent Clearance (CL/F) for TAK-137_101 | CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-inf), expressed in liters per hour (L/hr). | Day 1 | 
| Apparent Volume of Distribution (Vz/F) for TAK-137_101 | Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz. | Day 1 | 
| Total Amount of Drug (TAK-137) Excreted in Urine From Time 0 to Time t (Ae[0-t]) | Total amount of drug excreted in urine from time 0 to time t, calculated as Sum (Cu*Vu), where Cu is the concentration of drug excreted in urine and Vu is the volume of urine excreted. | Day 1 | 
| Fraction of TAK-137 Excreted in Urine (Fe) | Fraction of drug excreted in urine, calculated as Fe=(Ae[0-t]/dose)×100. | Day 1 | 
| Renal Clearance (CLr) for TAK-137 | CLr is a measure of apparent clearance of the drug from the urine, calculated as CLr=Ae(0-t)/AUC(0-96). | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug therapy